A patient has severe P. falciparum malaria and is unable to tolerate oral medications. Which regimen is the U.S. Food and Drug Administration (FDA)approved treatment of choice for this patient?
a) Intravenous quinidine gluconate plus intravenous doxycycline Vibramycin
b) Intravenous artesunate followed by atovaquone/proguanil Malarone
c) Intravenous quinine Qualaquin plus intravenous clindamycin
d) Intravenous mefloquine plus intravenous primaquine
Question 2
A patient who frequently travels to Africa has been treated for an acute attack of P. vivax malaria. The patient asks the nurse about medications to prevent relapse. Which response by the nurse is correct?
a) The form of malaria that you have does not relapse after a clinical cure has been achieved.
b) Until you are no longer traveling to Africa, relapse drugs will be postponed.
c) Using mosquito netting and DEET when you travel will prevent relapse.
d) You will be given prophylactic medications when you travel to prevent relapse.
Client on IV patient-controlled analgesia (PCA).
Electroencephalography (EEG). To perform the EEG, electrodes attached to the patient’s head pick up
Building competency in patient centered care
Graph showing oral administration of a single-dose drug. The time of onset is 2 hours and the end of ...
Malaria Ecology versus Incidence of Malaria